Diagnostic value of biochemical markers (Nash Test) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

BMC Gastroenterology

Volumn 6, Issue , 2006, Pages

  Poynard, Thierry ^a   Ratziu, Vlad ^a   Charlotte, Frederic ^a   Messous, Djamila ^a   Munteanu, Mona ^b   Imbert Bismut, Françoise ^a   Massard, Julien ^a   Bonyhay, Luninita ^a   Tahiri, Mohamed ^a   Thabut, Dominique ^a   Cadranel, Jean François ^c   Le Bail, Brigitte ^d   de Ledinghen, Victor ^d   Grimaldi, André ^a   Giral, Philippe ^a   Bruckert, Eric ^a   Turpin, Gérard ^a   Heurtier, Agnès ^a   Gombert, Sophie ^a   Lamaison, Francine ^a   Moussalli, Joseph ^a   Le Calvez, Sophie ^a   Benhamou, Yves ^a   D'Arrondel, Cecilia ^a   Cocaul, Arnaud ^a   Ravalet, Isabelle ^a   Combet, Stéphanie ^a   Podevin, Philippe ^e   Basdevant, Arnaud ^f   Slama, Gérard ^f   Clement, Karine ^f   Serfaty, Lawrence ^g   Housset, Chantal ^g   Capeau, Jacqueline ^g   Blanchi, Alain ^h   Pilette, Christophe ^h   Bourlière, Marc ⁱ   Oulès, Valérie ⁱ   Renou, Christophe ^j   Capron, Dominique ^k   Oberti, Frédéric ^l   Calès, Paul ^l   Tran, Albert ^m   Gelsi, Eve ^m   Gournay, Jérôme ⁿ   Vallet Pichard, Anais ^o   Pol, Stanislas ^o   Causse, Xavier ^p   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Department of Biopredictive ^*  (France)

^c Creil Hospital   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e Hôpital Pitié Salpêtrière ^*  (France)

^f HÔTEL DIEU   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h CENTRE HOSPITALIER DU MANS   (France)

ⁱ HÔPITAL SAINT JOSEPH   (France)

^j Hopital d'Hyeres   (France)

^k Hôpital d'Amiens   (France)

^l Hôpital d'Angers   (France)

^m Hôpital de Nice   (France)

ⁿ Service d'urologie Université et Hôpital de Nantes   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p Hôpital d'Orleans   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NONALCOHOLIC FATTY LIVER; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; ALGORITHM; ANALYTICAL EQUIPMENT; BIOPSY; BLOOD; CLINICAL TRIAL; FATTY LIVER; HEPATITIS; LIVER; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; REPRODUCIBILITY; STANDARD; VALIDATION STUDY;

ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; LIVER; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33845207096     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-6-34     Document Type: Article

References (49)

1. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-25.
2. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-31.
3. Charlton M: Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gostroenterol Hepatol 2004, 2:1048-58.
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
5. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35:1485-93.
6. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T: Liver fibrosis in over-weight patients. Gastroenterology 2000, 118:1117-1123.
7. Talwalkar JA: Motion - all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol 2002, 16:718-21.
8. Laurin J: Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 2002, 16:722-6.
9. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990, 99:1396-400.
10. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-81.
11. Poynard T, Ratziu V, Bedossa P: Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-8.
12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, for the LIDO Study Group: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
13. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, McCullough AJ: Non-alcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998, 11:560-565.
14. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-21.
15. Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004, 16:1087-93.
16. Sorbi D, Boynton J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatolhepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94:1018-1022.
17. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
18. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM: Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005, 15:3 10-5.
19. Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M: Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005, 15:1148-53.
20. Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Loberg E, Haaland T, Birkeland K, Bioro K: Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gostroenterol 2005, 40:1469-77.
21. Park KS, Lee YS, Park HW, Seo, SH, Jang BG, Hwang JY, Cho KB, Hwang JS, Ahn SH, Kang YN, Kim GC: Factors associated or related to with pathological severity of non-alcoholic fatty liver disease. Korean J Intern Med 2004, 19:19-26.
22. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A: Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005, 11:255-9.
23. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K: Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatagastroenterology 2005, 52:1549-53.
24. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M: Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gostroenterol 2003, 14:12-7.
25. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, Victor de Ledinghen V, Poynard T, for the LIDO Study Group and the CYTOL study group: Diagnostic Value of Biochemical Markers (FibroTest-FibroSURE) for the prediction of Liver Fibrosis in patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006, 6:6.
26. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-75.
27. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V: Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clin Chem 2004, 50:1344-55.
28. Poynard T, Imber-t-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
29. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-30.
30. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El HasnaouiP A, Slama A, Blin P, Thibault D, Parvaz P, Munteanu M, Trepo C: Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gast 2005, 100:1970-80. .
31. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T: Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3:167-74.
32. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429-34.
33. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-50.
34. Calles P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:13 73-81.
35. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella. A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J: The diagnostic value of biomarkers (Stea-toTest) for the prediction of liver steatosis. Comp Hepatol 2005, 4:10.
36. Thabut D, Naveau S, Frederic Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T: The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006, 52:1887-96.
37. DeLong ER, DeLong DM, Clarkelus DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-45.
38. Zhou X Obuchowski N, McClish D: In: Statistical Methods in Diagnostic Medicine. John Wiley & Sons I, ed. New York New York, 2002.
39. Rockey DC, Bissell DM: Noninvasive measures of liver fibrosis. Hepatology 2006, 43:S113-20.
40. Barrett AJ, Starkey PM: The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973, 133:709-24.
41. Gray RS, James K, Merriman J, Starkey IR, Elton RA, Clarke BF, Duncan LJ: Alpha 2-macroglobulin and proliferative retinopathy in type 1 diabetes. Horm Metab Res 1982, 14.389-92.
42. Chu CT, Rubenstein DS, Enghild JJ, Pizzo SV: Mechanism of insulin incorporation into alpha 2-macroglobulin: implications for the study of peptide and growth factor binding. Biochemistry 1991, 30:1551-60.
43. Westwood M, Aplin JD, Collinge IA, Gill A, White A, Gibson JM: alpha 2-macroglobulin: a new component in the insulin-like growth factor/ insulin-like growth factor binding protien-I axis. J Biol Chem 2001, 276:41668-74.
44. Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-57.
45. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
46. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher PA Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-92.
47. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R: Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004, 41:751-7.
48. Kunde SS, Lazenby AJ, Clements RH, Abrams GA: Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005, 42:650-6.
49. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J: Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005, 128:1146-8. author reply 1148.